LCTC Lifeloc Technologies Inc (PK)

 

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION 

Washington, D.C. 20549

 

 

FORM 8-K

 

 CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):  November 12, 2024

 

LIFELOC TECHNOLOGIES, INC.

(Exact name of registrant as specified in its charter)

 

Colorado		000-54319		84-1053680
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification Number)

 

12441 West 49th Ave., Unit 4
Wheat Ridge, CO		80033
(Address of Principal Executive Offices)		(Zip Code)

 

(303) 431-9500

(Registrant’s telephone number, including area code)

   

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: 

 

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	LCTC	N/A

  

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

Item 2.02

Results of Operations and Financial Condition.

 

On November 12, 2024, Lifeloc Technologies, Inc. (the “Company”) issued a press release announcing its operating results for the period ended September 30, 2024. This press release was made available on the Company’s website as of November 12, 2024. A copy of the press release is furnished herewith as Exhibit 99.1.

 

The information in this Form 8-K, including the exhibit attached hereto, is being “furnished” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any Company filing under the Securities Act of 1933, as amended, unless expressly set forth by specific reference in such filing that such information is incorporated by reference therein.

 

	Item 9.01	Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Press Release, dated November 12, 2024, issued by the Company
104	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date:  November 12, 2024	LIFELOC TECHNOLOGIES, INC.
	By:	/s/ Vern D. Kornelsen
		Chief Financial Officer and Secretary

 

 

 

Exhibit 99.1

 

 

Lifeloc Reports Third Quarter 2024 Results

WHEAT RIDGE, Colo., November 12, 2024 -- Lifeloc Technologies, Inc. (OTC: LCTC), a global leader in the development and manufacturing of breath alcohol and drug testing devices, has announced financial results for the quarter ended September 30, 2024.

Third Quarter Financial Highlights

Lifeloc posted quarterly net revenue of $2.087 million in the third quarter of 2024, resulting in a quarterly net loss of $(158) thousand, or $(0.06) per diluted share. These results compare to net revenue of $2.696 million and quarterly net profit of $110 thousand, or $0.04 per diluted share in the third quarter of 2023. Revenue for the quarter decreased 23% versus the third quarter last year. This decrease year-over-year was caused in part by sales in the third quarter last year benefitting from the relief of supply constraints, which allowed completion of order backlogs. Nine-month 2024 net revenues of $6.628 million and a net loss of $(740) thousand, or $(0.30) per diluted share, compared to net revenue of $7.140 million and a net profit of $111 thousand, or $0.05 per diluted share, for the same nine months of 2023. Total gross margin in the third quarter improved to 43.7% versus 41.5% for the same quarter last year. For the first nine months of 2024 gross margin was 41.4% versus 43.4% for the same period last year.

The gross margin improvement in the third quarter was primarily a result of product sales mix. The margin decline for the nine months of 2024 was a result of general cost inflation which the company is working to address through pricing. The losses for the quarter and year to date were caused primarily by the high research and development costs with the push to SpinDx commercialization.

We believe our core alcohol detection product line-up is strong. The L-series LX9 and LT7 units have features and performance that have driven market penetration by meeting previously unaddressable market needs, such as smart phone pairing, wider temperature use ranges and fast customization that incorporates local languages. We expect that sales of our newer L-series devices will be incremental to FC-series devices rather than displacing FC sales. The L-series devices have been certified to meet the requirements of most modern registration standards, such as SAI’s (Standards Australia International) latest AS 3547:2019 standards for Breath Alcohol Detectors. Our FC-series devices remain popular with many law enforcement and international organizations. Our Easycal® automated calibration station, the only automated calibration available for portable breath alcohol testers, builds valuable protection around our brand and contributes to market share gains by the workplace Phoenix® 6.0 BT and EV 30 devices.

We believe our most important goal and best opportunity remains the convergence of the global need for rapid detection of drugs of abuse with Lifeloc’s proven capability to build easy-to-use portable testing equipment. We are therefore focusing our research and development efforts on leveraging the SpinDx™ technology platform, sometimes referred to as “Lab on a Disk,” to develop a series of devices and tests that can be used at roadside and in emergency rooms, forensic labs and workplace test sites to achieve a rapid and quantitative measure for a panel of drugs of abuse. The initial product release is projected to be a device with a disk that allows for detection of delta-9-THC (the major intoxicating component of the cannabis plant) from a test subject’s saliva, followed by a disk for a panel of other drugs. SpinDx has been demonstrated in our laboratory to effectively detect for delta-9-THC, cocaine, fentanyl, amphetamine methamphetamine, morphine, MDMA, and benzodiazepines. Testing has validated the SpinDx measurement technology against the definitive standard liquid chromatography-mass spectroscopy (LCMS) measurement utilizing human samples.  The LCMS data have validated the SpinDx test results on real-world human saliva tests at a limit of detection of approximately 10 ng/ml. With our research and development work, we continue to improve our technology’s robustness, speed, and convenience of operation. We are currently performing validation testing of the microfluidic action and full drug assay within the current disk design before this transitions into production tooling. We plan to start beta testing of our SpinDx saliva testing system utilizing the delta-9-THC disks later this quarter using prototype readers as shown in the photograph below. Commercial launch of our first SpinDx application is projected to occur later in 2025. Following initial commercialization, we expect more offerings from this technology platform to include expanded drug panels and samples collected from blood and breath. Following the release of our SpinDx saliva testing system, we expect to accelerate development of combining our LX9 breathalyzer with the THC SpinDx detection unit, to produce our roadside marijuana breathalyzer system.

“We believe we are getting close to validating and launching our device into rapid drug testing,” said Dr. Wayne Willkomm, Lifeloc’s chief executive officer. “We anticipate continued high research and development expenses in this final push toward commercialization. With the rising demand for saliva drug testing, the initial release of SpinDx to the market becomes more urgent and valuable.”

In anticipation of declining cash because of the high research and development investment in SpinDx, the company has sought to strengthen its financial resources. Early in the third quarter the Company closed on a $750,000 line of credit with Citywide Banks as well as a private placement of 210,000 shares of the Company’s common stock at $3.80 per share, resulting in a $798,000 capital injection to assist the SpinDx development in moving forward to testing and commercialization.

“The small private placement was very efficient,” said Dr. Willkomm, “with no underwriting costs and minimizing shareholder dilution.”

 

About Lifeloc Technologies

Lifeloc Technologies, Inc. (OTC: LCTC) is a trusted U.S. manufacturer of evidential breath alcohol testers and related training and supplies for Workplace, Law Enforcement, Corrections and International customers. Lifeloc stock trades over-the-counter under the symbol LCTC. We are a fully reporting Company with our SEC filings available on our web site, www.lifeloc.com/investor.

Forward Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which involve substantial risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. All forward-looking statements expressed or implied in this press release, including statements about our strategies, performance, expectations about new and existing products, market demand, economic conditions, acceptance of new and existing products, technologies and opportunities, market size and growth, and return on investments in products and market, are based on information available to us on the date of this document, and we assume no obligation to update such forward-looking statements. Investors are strongly encouraged to review the section titled “Risk Factors” in our SEC filings.

Phoenix® and Easycal® are registered trademarks of Lifeloc Technologies, Inc.

SpinDx™ is a trademark of Sandia Corporation.

Amy Evans 
Lifeloc Technologies, Inc. 
http://www.lifeloc.com 
(303) 431-9500

 

 

LIFELOC TECHNOLOGIES, INC.
Condensed Balance Sheets (Unaudited)

ASSETS
		September 30, 2024				December 31, 2023
CURRENT ASSETS:
Cash		$	841,621			$	1,766,621
Accounts receivable, net			611,439				812,126
Inventories, net			3,160,200				3,024,834
Federal and state income taxes receivable			60,420				—
Prepaid expenses and other			89,049				105,967
Total current assets			4,762,729				5,709,548
PROPERTY AND EQUIPMENT, at cost:
Land			317,932				317,932
Building			1,928,795				1,928,795
Real-time Alcohol Detection And Recognition equipment and software			569,448				569,448
Production equipment, software and space modifications			1,349,839				1,154,803
Training courses			432,375				432,375
Office equipment, software and space modifications			254,333				216,618
Sales and marketing equipment and space modifications			226,356				226,356
Research and development equipment, software and space modifications			725,556				480,684
Research and development equipment, software and space modifications not in service			147,615				—
Less accumulated depreciation			(3,511,125	)			(3,326,837	)
Total property and equipment, net			2,441,124				2,000,174
OTHER ASSETS:
Patents, net			80,517				64,439
Deposits and other			12,261				111,157
Deferred taxes			1,046,493				806,652
Total other assets			1,139,271				982,248
Total assets		$	8,343,124			$	8,691,970
LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES:
Accounts payable		$	328,528			$	402,231
Term loan payable, current portion			52,789				51,588
Income taxes payable			—				44,952
Customer deposits			28,940				195,719
Accrued expenses			270,932				329,311
Deferred revenue, current portion			56,090				79,036
Reserve for warranty expense			46,500				46,500
Total current liabilities			783,779				1,149,337
TERM LOAN PAYABLE, net of current portion and debt issuance costs			1,132,066				1,170,243
DEFERRED REVENUE, net of current portion			8,575				11,565
Total liabilities			1,924,420				2,331,145
COMMITMENTS AND CONTINGENCIES (Note 5)							—
STOCKHOLDERS' EQUITY:
Common stock, no par value; 50,000,000 shares authorized, 2,664,116 shares  outstanding at September 30, 2024 (2,454,116 outstanding at December 31, 2023)			5,466,014				4,668,014
Retained earnings			952,690				1,692,811
Total stockholders' equity			6,418,704				6,360,825
Total liabilities and stockholders' equity		$	8,343,124			$	8,691,970

 

 

 

 

LIFELOC TECHNOLOGIES, INC.

Condensed Statements of Income (Loss) (Unaudited)

 

		Three Months Ended September 30,
REVENUES:		2024				2023
Product sales		$	2,075,994			$	2,676,872
Royalties			3,016				5,063
Rental income			8,316				13,573
Total			2,087,326				2,695,508
COST OF SALES			1,175,374				1,576,117
GROSS PROFIT			911,952				1,119,391
OPERATING EXPENSES:
Research and development			521,107				516,174
Sales and marketing			329,716				309,898
General and administrative			269,450				269,593
Total			1,120,273				1,095,665
OPERATING INCOME (LOSS)			(208,321	)			23,726
OTHER INCOME (EXPENSE):
Interest income			9,525				17,678
Interest expense			(10,019	)			(10,494	)
Total			(494	)			7,184
NET INCOME (LOSS) BEFORE BENEFIT FROM (PROVISION FOR) TAXES			(208,815	)			30,910
BENEFIT FROM FEDERAL AND STATE INCOME TAXES			50,488				78,693
NET INCOME (LOSS)		$	(158,327	)		$	109,603
NET INCOME (LOSS) PER SHARE, BASIC		$	(0.06	)		$	0.04
NET INCOME (LOSS) PER SHARE, DILUTED		$	(0.06	)		$	0.04
WEIGHTED AVERAGE SHARES, BASIC			2,611,616				2,454,116
WEIGHTED AVERAGE SHARES, DILUTED			2,611,616				2,454,116

=

LIFELOC TECHNOLOGIES, INC.

Condensed Statements of Income (Loss) (Unaudited)

		Nine Months Ended September 30,
REVENUES:		2024				2023
Product sales		$	6,580,861			$	7,056,638
Royalties			22,776				23,419
Rental income			24,462				60,351
Total			6,628,099				7,140,408
COST OF SALES			3,887,244				4,043,146
GROSS PROFIT			2,740,855				3,097,262
OPERATING EXPENSES:
Research and development			1,738,982				1,308,721
Sales and marketing			1,040,099				897,856
General and administrative			947,384				872,724
Total			3,726,465				3,079,301
OPERATING INCOME (LOSS)			(985,610	)			17,961
OTHER INCOME (EXPENSE):
Interest income			35,874				46,678
Interest expense			(30,226	)			(31,319	)
Total			5,648				15,359
NET INCOME (LOSS) BEFORE BENEFIT FROM (PROVISION FOR) TAXES			(979,962	)			33,320
BENEFIT FROM FEDERAL AND STATE INCOME TAXES			239,841				77,640
NET INCOME (LOSS)		$	(740,121	)		$	110,960
NET INCOME (LOSS) PER SHARE, BASIC		$	(0.30	)		$	0.05
NET INCOME (LOSS) PER SHARE, DILUTED		$	(0.30	)		$	0.05
WEIGHTED AVERAGE SHARES, BASIC			2,506,999				2,454,116
WEIGHTED AVERAGE SHARES, DILUTED			2,506,999				2,454,116

 

Lifeloc Technologies, Inc.

Statements of Stockholders' Equity (Unaudited)

		Three Months Ended September 30,								Nine Months Ended September 30,
		2024				2023				2024				2023
Beginning balances		4,668,014				4,668,014				4,668,014				4,668,014
Beginning balances		1,111,017				1,488,554				1,692,811				1,487,197
Total stockholders' equity, beginning balances		$	5,779,031			$	6,156,568			$	6,360,825			$	6,155,211
Common stock:
Beginning balances			4,668,014				4,668,014				4,668,014				4,668,014
Issuance of 210,000 shares at $3.80 per share			798,000				—				798,000				—
Net income (loss)			—				—				—				—
Ending balances			5,466,014				4,668,014				5,466,014				4,668,014
Retained earnings:
Beginning balances			1,111,017				1,488,554				1,692,811				1,487,197
Net income (loss)			(158,327	)			109,603				(740,121	)			110,960
Ending balances			952,690				1,598,157				952,690				1,598,157
Beginning balances			5,779,031				6,156,568				6,360,825				6,155,211
Net income (loss)			(158,327)				109,603				(740,121)				110,960
Total stockholders' equity, ending balances		$	6,418,704			$	6,266,171			$	6,418,704			$	6,266,171

 

LIFELOC TECHNOLOGIES, INC.

Condensed Statements of Cash Flows (Unaudited)

		Nine Months Ended September 30,
CASH FLOWS FROM OPERATING ACTIVITIES:		2024				2023
Net income (loss)		$	(740,121	)		$	110,960
Adjustments to reconcile net income (loss) to net cash (used in) operating activities-
Depreciation and amortization			193,096				198,471
Provision for doubtful accounts, net change			1,000				—
Provision for inventory obsolescence, net change			52,500				—
Deferred taxes, net change			(239,841	)			(114,116	)
Changes in operating assets and liabilities-
Accounts receivable			199,687				(81,388	)
Inventories			(187,866	)			(179,943	)
Federal and state income taxes receivable			(60,420	)			107,575
Prepaid expenses and other			16,918				(207,149	)
Deposits and other			98,896				—
Accounts payable			(73,703	)			87,870
Income taxes payable			(44,952	)			36,476
Customer deposits			(166,779	)			(16,557	)
Accrued expenses			(58,379	)			(82,738	)
Deferred revenue			(25,936	)			(13,339	)
Net cash (used in) operating activities			(1,035,900	)			(153,878	)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment			(477,623	)			(21,611	)
Purchases of research and development equipment, software, and space modifications not in service			(147,615	)			—
Patent filing expense			(21,708	)			(1,404	)
Net cash (used in) investing activities			(646,946	)			(23,015	)
CASH FLOWS FROM FINANCING ACTIVITIES:
Principal payments made on term loan			(40,154	)			(38,988	)
Proceeds from issuance of 210,000 shares of common stock at $3.80 per share			798,000				—
Net cash provided by (used in) financing activities			757,846				(38,988	)
NET (DECREASE) IN CASH			(925,000	)			(215,881	)
CASH, BEGINNING OF PERIOD			1,766,621				2,352,754
CASH, END OF PERIOD		$	841,621			$	2,136,873
SUPPLEMENTAL INFORMATION:
Cash paid for interest		$	27,048			$	28,091
Cash paid for income tax		$	60,420			$	—

 

v3.24.3

Cover	Nov. 12, 2024
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Nov. 12, 2024
Entity File Number	000-54319
Entity Registrant Name	LIFELOC TECHNOLOGIES, INC.
Entity Central Index Key	0001493137
Entity Tax Identification Number	84-1053680
Entity Incorporation, State or Country Code	CO
Entity Address, Address Line One	12441 West 49th Ave.
Entity Address, Address Line Two	Unit 4
Entity Address, City or Town	Wheat Ridge
Entity Address, State or Province	CO
Entity Address, Postal Zip Code	80033
City Area Code	(303)
Local Phone Number	431-9500
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock
Trading Symbol	LCTC
Entity Emerging Growth Company	false

---